Form 57.124 Antimicrobial Use and Resistance (AUR): Pharmacy Data Mo

Form Approved

OMB No. 0920-0666

Exp. Date: 12/31/2026

www.cdc.gov/nhsn

Antimicrobial Use and Resistance (AUR): Pharmacy Data

Monthly Electronic Upload Specification Tables

These data will be collected in an aggregate monthly electronic file transfer from the facility to NHSN via Clinical Document Architecture (CDA).

Table 1. CDA File Descriptors				These data elements will be transmitted with each month’s report.
Variable Name		Description of Variable
Facility OID		NHSN Facility ID number
Application OID		Vendor software ID number
SDS validation ID		ID provided by NHSN Team confirming vendor software passed validation
location		NHSN location code
month		Denominator month
year		Denominator year
Table 2. Aggregate Patient Information					These data elements are aggregated to the location and facility wide inpatient level for each month.
Variable Name		Description of Variable
numDaysPresent		Total number of days present
numTherapyDays		Number of therapy days
numAdmissions		Number of admissions
Table 3. Aggregate Pharmacy Information						These data elements are obtained from the facility’s electronic medication administration record (eMAR) or bar coding medication administration (BCMA) and aggregated to the location and facility wide inpatient level for each month.
Variable Name		Description of Variable					Examples
drugIngredient		Antimicrobial ingredient					(see Table 3a)
routeDrugAdmin		Route of administration					Digestive tract, respiratory tract, intravenous route, intramuscular route
Table 3a. List of Antimicrobials Accepted						This is the list of antimicrobials currently accepted into NHSN as part of the antimicrobial use reporting.
Amantadine	Baloxavir marboxil		Cefpodoxime		Clindamycin			Fluconazole	Metronidazole	Penicillin V	Tedizolid
Amikacin	Caspofungin		Cefprozil		Colistimethate			Fosfomycin	Micafungin	Peramivir	Telavancin
Amikacin Liposomal	Cefaclor		Ceftaroline		Colistin			Gemifloxacin	Minocycline	Piperacillin/ Tazobactam	Tetracycline
Amoxicillin	Cefadroxil		Ceftazidime		Dalbavancin			Gentamicin	Molnupiravir	Pivmecillinam	Tigecycline
Amoxicillin/ Clavulanate	Cefazolin		Ceftazidime/ Avibactam		Daptomycin			Imipenem/ Cilastatin	Moxifloxacin	Plazomicin	Tinidazole
Amphotericin B	Cefdinir		Ceftobiprole medocaril		Delafloxacin			Imipenem/ Cilastatin/ Relebactam	Nafcillin	Polymyxin B	Tobramycin
Amphotericin B lipid complex	Cefepime		Ceftolozane/ Tazobactam		Dicloxacillin			Isavuconazonium	Nirmatrelvir	Posaconazole	Vancomycin
Amphotericin B liposomal	Cefepime/ Enmetazobactam		Ceftriaxone		Doxycycline			Itraconazole	Nitrofurantoin	Quinupristin/ Dalfopristin	Voriconazole
Ampicillin	Cefiderocol		Cefuroxime		Eravacycline			Lefamulin	Omadacycline	Remdesivir	Zanamivir
Ampicillin/ Sulbactam	Cefixime		Cephalexin		Ertapenem			Levofloxacin	Oritavancin	Rezafungin
Anidulafungin	Cefotaxime				Erythromycin			Linezolid	Oseltamivir	Rifampin	*Addition pending FDA approval of the drug in Sept 2024
Azithromycin	Cefotetan		Ciprofloxacin		Etzadroxil/ Probenecid*			Meropenem	Oxacillin	Rimantadine
Aztreonam	Cefoxitin		Clarithromycin		Fidaxomicin			Meropenem/ Vaborbactam	Penicillin G	Sulfamethoxazole/ Trimethoprim
Assurance of Confidentiality:  The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)). Public reporting burden of this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering, and maintaining the data needed, and completing and reviewing the collection of information.  An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number.  Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS H21-8, Atlanta, GA 30333, ATTN:  PRA (0920-0666). CDC 57.124 v9, 13.0

Page 5 of 5